Nucleic acid-based therapeutics such as siRNAs and ASOs enable the post-transcriptional silencing or modulation of genes implicated in AD, including ApoE4, APP, BACE1, or tau [76,142,143,144]. The gene discussed is MAPT; the disease is Alzheimer disease.